GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Pramlintide

Company
Cheryl Rosenfeld, DO
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Pramlintide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07506369

    Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

    Not yet reported University Hospital, Gentofte, Copenhagen 18 participants Est. completion 2028-10 1 site
    Other conditions: Obesity & Overweight
    View official trial listing →
  • Completed NCT NCT00042458

    Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

    Not yet reported AstraZeneca 296 participants Est. completion 2003-03 33 sites
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT00042471

    Evaluation of the Bioavailability of Pramlintide

    Not yet reported AstraZeneca 75 participants Est. completion 2002-12 4 sites Stand-alone
    Type 2 diabetes Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT00042601

    Evaluation of the Effect of Pramlintide on Satiety and Food Intake

    Not yet reported AstraZeneca 51 participants Est. completion 2003-10 1 site
    Type 2 diabetes Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT00044707

    Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide

    Not yet reported AstraZeneca 24 participants Est. completion 2002-09 1 site
    Other conditions: Diabetes Mellitus, Non-Insulin-Dependent
    View official trial listing →
  • Completed NCT NCT00107107

    Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

    Not yet reported AstraZeneca 190 participants Est. completion 2005-06 25 sites
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT00108004

    Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 400 participants Est. completion 2005-06 48 sites Stand-alone
    Type 2 diabetes Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00112021

    A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

    Not yet reported AstraZeneca 400 participants Est. completion 2005-11 21 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT00189514

    A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

    Not yet reported AstraZeneca 210 participants Est. completion 2007-06 21 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT00206258

    The Role of Amylin and Glucagon in T1DM

    Not yet reported Baylor College of Medicine 30 participants Est. completion 2005-08 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT00206297

    The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes

    Not yet reported Baylor College of Medicine 20 participants Est. completion 2006-02 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT00229658

    An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

    AstraZeneca 1297 participants Est. completion 2008-05 107 sites
    Type 2 diabetes Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00240253

    A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 200 participants Est. completion 2006-06 34 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00291772

    Continuous Subcutaneous Infusion of Pramlintide and Insulin

    Not yet reported Baylor College of Medicine 13 participants Est. completion 2007-11 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT00313183

    A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus

    Not yet reported AstraZeneca 12 participants Est. completion 2007-08 3 sites Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00392925

    A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

    Not yet reported AstraZeneca 177 participants Est. completion 2007-09 12 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT00402077

    A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

    Not yet reported AstraZeneca 258 participants Est. completion 2007-08 16 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT00442767

    Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus

    Not yet reported Montefiore Medical Center 8 participants Est. completion 2009-02 1 site Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00444561

    Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

    Not yet reported AstraZeneca 184 participants Est. completion 2005-05 10 sites
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT00460304

    The Effect of Pramlintide on Meal Time Insulin Bolus

    Not yet reported Diabetes Care Center 12 participants Est. completion 2008-11
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT00467649

    A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

    Not yet reported AstraZeneca 112 participants Est. completion 2008-04 37 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00489645

    Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide

    Not yet reported Ludwig-Maximilians - University of Munich 27 participants Est. completion 2007-04 Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT00502138

    A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

    Not yet reported University Diabetes & Endocrine Consultants 12 participants Est. completion 2008-01 1 site Stand-alone
    Other conditions: IDDM
    View official trial listing →
  • Withdrawn NCT NCT00505882

    Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

    Not yet reported University of Texas Southwestern Medical Center Est. completion 2008-12 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT00673387

    Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

    Not yet reported AstraZeneca 636 participants Est. completion 2009-10 36 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT00690235

    Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

    Not yet reported University of Texas Southwestern Medical Center 33 participants Est. completion 2011-08 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
    View official trial listing →
  • Status unknown NCT NCT00691158

    A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

    Not yet reported Oregon Health and Science University 10 participants Est. completion 2024-07 1 site
    Other conditions: Obesity
    View official trial listing →
  • Withdrawn NCT NCT00732147

    Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

    Not yet reported University of Maryland, Baltimore Est. completion 2011-04 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT00790699

    Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

    Not yet reported Texas Diabetes & Endocrinology, P.A. 31 participants Est. completion 2011-11 1 site
    Type 2 diabetes Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT00819234

    Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

    Not yet reported AstraZeneca 274 participants Est. completion 2009-11 33 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT00842075

    Pramlintide in Adolescents With Type 1 Diabetes

    Not yet reported University of Colorado, Denver 10 participants Est. completion 2009-12 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT00950677

    The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes

    Not yet reported Baylor College of Medicine 16 participants Est. completion 2011-05 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT01137695

    Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

    Not yet reported Cheryl Rosenfeld, DO 40 participants Est. completion 2012-04 3 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT01165944

    Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus

    Not yet reported, Not yet reported University of Colorado, Denver Est. completion 2011-08 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Terminated NCT NCT01235741

    A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

    Not yet reported AstraZeneca 213 participants Est. completion 2011-09 18 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT01269008

    Closed Loop System With Pramlintide Versus Exenatide

    Not yet reported Albert Einstein College of Medicine 13 participants Est. completion 2013-01 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT01269047

    Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

    Not yet reported Albert Einstein College of Medicine 37 participants Est. completion 2016-12 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Terminated NCT NCT01434862

    Pramlintide Combined With Model Predictive Control Algorithm

    Not yet reported University of Virginia 2 participants Est. completion 2012-02 1 site Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01708044

    Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM

    Not yet reported AstraZeneca 32 participants Est. completion 2013-09 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT01839370

    Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus

    Not yet reported University of Virginia 9 participants Est. completion 2013-11 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT01841359

    Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

    Not yet reported Joslin Diabetes Center 22 participants Est. completion 2022-02-08 1 site Stand-alone
    Other conditions: Hypoglycemia, Evidence of Previous Gastric Surgery
    View official trial listing →
  • Completed NCT NCT02500979

    Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

    Not yet reported AstraZeneca 34 participants Est. completion 2016-08-05 3 sites Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02814123

    Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes

    Not yet reported McGill University 28 participants Est. completion 2018-07-08 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT03512236

    A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus

    Not yet reported Adocia 24 participants Est. completion 2019-02-14 1 site
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Terminated NCT NCT03547427

    Glucagon Counterregulation in Type 1 Diabetes

    Not yet reported University of Virginia 13 participants Est. completion 2019-03-11 1 site Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Active, not recruiting NCT NCT03560960

    Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

    Not yet reported Boston University 57 participants Est. completion 2026-11 3 sites Stand-alone
    Other conditions: Alzheimer Disease, Mild Cognitive Impairment
    View official trial listing →
  • Completed NCT NCT03598075

    Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients

    Not yet reported Danish Headache Center 36 participants Est. completion 2019-12-31 1 site
    Other conditions: Migraine Without Aura
    View official trial listing →
  • Completed NCT NCT03800875

    Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting

    Not yet reported McGill University 24 participants Est. completion 2020-09-19 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT03916640

    A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus

    Not yet reported Adocia 24 participants Est. completion 2019-03-01 1 site Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT03981627

    A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus

    Not yet reported, Not yet reported Adocia 44 participants Est. completion 2020-06-27 1 site Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT03993366

    Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement

    Not yet reported McGill University 8 participants Est. completion 2019-08-06 1 site Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT04074317

    Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

    Not yet reported Xeris Pharmaceuticals 18 participants Est. completion 2020-04-02 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT04163874

    Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas

    Not yet reported McGill University 36 participants Est. completion 2022-01-30 1 site
    Other conditions: Type 1 Diabetes, Type 1 Diabetes Mellitus, Hyperglycemia, Postprandial
    View official trial listing →
  • Status unknown NCT NCT04243629

    Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes

    Not yet reported McGill University 26 participants Est. completion 2024-04 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type 1, Type 1 Diabetes, Postprandial Hyperglycemia
    View official trial listing →
  • Withdrawn NCT NCT04252612

    Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute Est. completion 2023-06-26 1 site Stand-alone
    Other conditions: Cutaneous Squamous Cell Carcinoma
    View official trial listing →
  • Status unknown NCT NCT04972175

    Safety and Efficacy of BC LisPram

    Not yet reported Michael Tsoukas 16 participants Est. completion 2022-06 1 site
    Other conditions: Type1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT05199714

    A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes

    Not yet reported McGill University Health Centre/Research Institute of the McGill University Health Centre 12 participants Est. completion 2023-03-25 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Status unknown NCT NCT06046417

    A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes

    Not yet reported, Not yet reported McGill University Health Centre/Research Institute of the McGill University Health Centre 30 participants Est. completion 2025-06 1 site Stand-alone
    Other conditions: type1diabetes, Diabetes Mellitus, Type 1
    View official trial listing →
  • Status unknown NCT NCT06186063

    The Role of Amylin in Bone Metabolism

    Not yet reported Filip Krag Knop 20 participants Est. completion 2024-08-01 1 site Stand-alone
    Other conditions: Bone Diseases, Metabolic, Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT06422325

    Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide

    Not yet reported Oregon Health and Science University 33 participants Est. completion 2025-01-28 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Withdrawn NCT NCT06619015

    Tailoring Obesity Treatment Trial

    Not yet reported, Not yet reported Esbjerg Hospital - University Hospital of Southern Denmark Est. completion 2025-04-01 1 site Added to GLP-1
    Prediabetes Other conditions: Obesity, Appetite Regulation
    View official trial listing →
  • Not yet recruiting NCT NCT07340775

    Hypersensitivity to Amylin in Post-Traumatic Headache

    Not yet reported Danish Headache Center 21 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Headache Disorders, Secondary, Brain Diseases, Headache Disorders, Nervous System Diseases, Central Nervous System Diseases, Neurologic Manifestations, Signs and Symptoms, Pathological Conditions, Signs and Symptoms, Post-Traumatic Headache, Pain, Peptide Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Peptides, Amino Acids, Peptides, and Proteins, Amylin, Pramlintide
    View official trial listing →
  • Not yet recruiting NCT NCT07340788

    Amylin-Induced Migraine Attacks Without Aura

    Not yet reported Danish Headache Center 21 participants Est. completion 2028-10-30 1 site Stand-alone
    Other conditions: Headache Disorders, Primary, Headache Disorders, Brain Diseases, Nervous System Diseases, Central Nervous System Diseases, Neurologic Manifestations, Signs and Symptoms, Pathological Conditions, Signs and Symptoms, Migraine Disorders, Headache, Pain, Peptide Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Peptides, Amino Acids, Peptides, and Proteins, Amylin, Pramlintide
    View official trial listing →
  • Not yet recruiting NCT NCT07679516

    Postprandial Regulation of Bone Perfusion in Healthy Individuals

    Not yet reported University of Copenhagen 15 participants Est. completion 2028-05 1 site
    Other conditions: Healthy Adult Participants, Bone Physiology, Bone Blood Flow Regulation, Peptide Hormones
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Pramlintide, Pramlintide (Amylin)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.